Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy

被引：130
|
作者：
Thibodeau, Jacques [1 ]
Bourgeois-Daigneault, Marie-Claude [1 ]
Lapointe, Rejean [2 ,3 ]
机构：
[1] Univ Montreal, Dept Microbiol & Immunol, Lab Immunol Mol, Montreal, PQ H3C 3J7, Canada
[2] Univ Montreal, Notre Dame Hosp, CRCHUM, Montreal, PQ H3C 3J7, Canada
[3] Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada
来源：
ONCOIMMUNOLOGY | 2012年 / 1卷 / 06期
基金：
加拿大健康研究院;
关键词：
cancer; HLA; immunotherapy; MHC Class II; tumor; vaccine; CD4(+) T-CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; INVARIANT CHAIN; HLA-DR; TUMOR-CELLS; METASTATIC MELANOMA; IMMUNE-RESPONSE; B-CELLS; EXPRESSION; CIITA;
D O I：
10.4161/onci.21205
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The success of immunotherapy relies on the participation of all arms of the immune system and the role of CD4(+) T lymphocytes in preventing tumor growth is now well established. Understanding how tumors evade immune responses holds the key to the development of cancer immunotherapies. In this review, we discuss how MHC Class II expression varies in cancer cells and how this influences antitumor immune responses. We also discuss the means that are currently available for harnessing the MHC Class II antigen presentation pathway for the development of efficient vaccines to activate the immune system against cancer.
引用
收藏
页码：908 / 916
页数：9
相关论文
共 50 条
12345